Search results for: Value-Based Pricing
Filter search results
Defining Benefit Through Willingness to Pay
24 August 2010
…about the pricing and reimbursement of prescription medicines. Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
…accelerated review, improved health technology assessment (HTA), and pricing and reimbursement (P&R) reforms, (2) AMCs create incentives only in the markets to which they are applied and the inclusion of…
Save the Date: Drug Development in 2022, OHE’s 50th Anniversary Conference
21 June 2012
…Professor Patricia Danzon, The Wharton School, University of Pennsylvania Dr Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency Dr Jens Grueger, Head, Global Health Economics and Pricing, Roche Pharmaceuticals Dr…
Reasons for Discontinuation of R&D Projects: Lead and Follow-on Indications
12 March 2013
…issue in context, he noted that an uncertain and changing pricing and reimbursement environment and the high costs of R&D have nudged companies into focusing on higher risk therapeutic areas…
The Economics of the Market for Medicines: 2013 Review
26 March 2013
OHE’s Dr Jorge Mestre-Ferrandiz is a visiting lecturer in the Department of Economics at City University London. As part of his 2013 activities, he recently gave a comprehensive lecture on…
Orphan Drugs Policies: A Suitable Case for Treatment
20 May 2014
…towards better public policy. How orphan drugs may be best assessed to determine pricing and reimbursement continues to present challenges. Towse and Drummond identify the primary challenges this has presented,…
OHE in the BMJ: Reforming the Cancer Drug Fund, and Reviving the PROMs Programme
10 December 2014
…The CDF would pay for commissioning (where use with research was practicable) and the company would (usually) fund and undertake the research. Flexible pricing agreements might be needed. NICE would…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…Value: Insights from the Experts panel discussion, Indianapolis, on 1 March 2016. Paula presented a paper which discusses issues with going ‘beyond quality adjusted life years (QALYs)’ when valuing health…
OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?
16 January 2020
…and pricing patterns. Some empirical examples will be discussed to illustrate these points. Dr Alistair McGuire is Professor of the Department of Health Policy at London School of Economics. Prior to…